The Pediatric Rare Disease Voucher Program Is Set To Sunset

While I do not have a crystal ball, I can tell you this: the program has been renewed before and is one of the most popular mechanisms by which small pharma/biotech (like most of my clients) can enter the drug development space. In my experience, getting Pediatric Rare Disease designation early in development makes it much more possible to fund clinical trials.